Skip to main content

Table 5 Details of comedications classified as “contraindication (Red)” for GEL/PIB group

From: Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan

 

GLE/PIB

Total

6,871

Atazanavir alone

0

0.0%

Atorvastatin

36

0.5%

Aliskiren

0

0.0%

Amobarbital

1

0.0%

Apalutamide

0

0.0%

Bosentan

2

0.0%

Carbamazepine

29

0.4%

Dabigatran

13

0.2%

Darunavir/cobicistat/FTC/TAF

0

0.0%

Darunavir/cobicistat

0

0.0%

Desogestrel/ethinylestradiol (COC)

0

0.0%

Drospirenone/ethinyl estradiol (COC)

2

0.0%

Efavirenz

0

0.0%

Eltrombopag

3

0.0%

Ethinyl estradiol

0

0.0%

Etravirine

0

0.0%

Fosamprenavir

0

0.0%

Ledipasvir/Sofosbuvir

2

0.0%

Levonorgestrel/ethinyl estradiol (COC)

0

0.0%

Lopinavir

0

0.0%

Nevirapine

0

0.0%

Nirmatrelvir/ritonavir

0

0.0%

Norethisterone (Norethindrone)/ethinyl estradiol (COC)

3

0.0%

Norgestrel/ethinyl estradiol (COC)

0

0.0%

Phenobarbital

10

0.1%

Phenytoin

13

0.2%

Primidone

2

0.0%

Rifabutin

0

0.0%

Rifampicin

0

0.0%

Ritonavir

0

0.0%

Simvastatin

7

0.1%

Sofosbuvir/Velpatasvir

0

0.0%

Vinblastine

0

0.0%

Vincristine

2

0.0%

  1. The denominators for percentage calculation were the total number of cases in GLE/PIB group